Baker Bros bags $340m from BeiGene block

Rashmi Kumar

December 02, 2020 06:15 am

Healthcare medical biopharmaceutical investing stock chart background | Kurhan - stock.adobe.com

Baker Bros Advisors, a shareholder in Chinese biopharmaceutical company BeiGene, has raised $340.1m from a sell-down of the firm’s American depositary shares.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Health and Biotech Equity China Americas Asia Greater China Northeast Asia Asia Pacific ABBs-Block Trades United States Emerging Markets North America SRI Goldman Sachs

RK

Rashmi Kumar